Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LORI A LESLIE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1972746394
CMS profile
362037
Location
HACKENSACK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$119,577.63

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
BeiGene USA, Inc. $35,484.29 18
Kite Pharma, Inc. $21,200.00 9
Epizyme, Inc., $16,520.00 12
AstraZeneca Pharmaceuticals LP $15,264.99 12
Seagen Inc. $7,462.92 6
Pharmacyclics LLC, An AbbVie Company $6,942.96 8
Janssen Scientific Affairs, LLC $4,972.50 2
Janssen Biotech, Inc. $4,265.00 4
Merck Sharp & Dohme Corporation $4,000.00 1
AbbVie Inc. $3,000.00 4
TG THERAPEUTICS, INC. $450.00 1
E.R. Squibb & Sons, L.L.C. $14.97 1

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LORI A LESLIE

NPI 1972746394 · CMS profile ID 362037

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

HACKENSACK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972746394?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LORI A LESLIE, NPI 1972746394, CMS profile ID 362037. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972746394?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). LORI A LESLIE, NPI 1972746394, CMS profile ID 362037. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972746394?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
LORI A LESLIE, NPI 1972746394, CMS profile ID 362037, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1972746394?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $119,577.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
BeiGene USA, Inc. $1,375.0004/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846696103 CMS
Kite Pharma, Inc. $1,890.0004/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844416999 CMS
Kite Pharma, Inc. $1,890.0004/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844417003 CMS
AstraZeneca Pharmaceuticals LP $1,100.0004/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829585657 CMS
BeiGene USA, Inc. $1,375.0004/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846696101 CMS
Pharmacyclics LLC, An AbbVie Company $18.7304/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781017237 CMS
Kite Pharma, Inc. $2,910.0004/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844417007 CMS
Pharmacyclics LLC, An AbbVie Company $1,500.0004/06/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781017235 CMS
AstraZeneca Pharmaceuticals LP $14.9903/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829725269 CMS
Epizyme, Inc., $2,655.0003/31/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832341293 CMS
BeiGene USA, Inc. $1,650.0003/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846696105 CMS
Pharmacyclics LLC, An AbbVie Company $6.0003/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781017233 CMS
AstraZeneca Pharmaceuticals LP $300.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830016101 CMS
BeiGene USA, Inc. $1,375.0003/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846696109 CMS
Seagen Inc. $1,235.0002/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832185947 CMS
BeiGene USA, Inc. $1,375.0002/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846696107 CMS
Seagen Inc. $1,100.0002/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832185927 CMS
Kite Pharma, Inc. $2,600.0002/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844416983 CMS
AstraZeneca Pharmaceuticals LP $1,100.0002/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829537305 CMS
BeiGene USA, Inc. $1,375.0002/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846696095 CMS
BeiGene USA, Inc. $3,850.0002/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846696099 CMS
AstraZeneca Pharmaceuticals LP $1,665.0002/02/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830053217 CMS
Epizyme, Inc., $1,180.0001/29/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832341289 CMS
Epizyme, Inc., $1,180.0001/29/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832341291 CMS
BeiGene USA, Inc. $1,375.0001/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846696097 CMS
Epizyme, Inc., $2,065.0001/28/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832341287 CMS
Janssen Scientific Affairs, LLC $1,950.0001/04/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788881977 CMS
Epizyme, Inc., $1,770.0001/01/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832341285 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $56,179.04 51
PY2020 $100,240.40 85
PY2021 $119,577.63 78
PY2022 $131,375.65 87
PY2023 $118,527.37 91
PY2024 $104,214.76 68
PY2025 $34,899.41 29

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,697,787.14 162
PY2024 Principal investigator $2,248,943.87 274
PY2023 Principal investigator $2,557,435.47 271
PY2022 Principal investigator $1,660,583.78 163
PY2021 Recipient $15.58 1
PY2021 Principal investigator $1,246,262.05 125
PY2020 Principal investigator $1,149,818.73 57
PY2019 Recipient $1,306.79 6
PY2019 Principal investigator $658,218.85 28

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

162 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $600.00 12/24/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184128450
Principal investigator 1 BeOne Medicines Ltd. $2,604.00 12/23/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330845
Principal investigator 1 Genmab A/S $282.00 12/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923675
Principal investigator 1 Genmab A/S $2,720.00 12/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923708
Principal investigator 1 Genmab A/S $20,509.00 12/19/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923726
Principal investigator 1 Genmab A/S $1,798.00 12/19/2025 Non-covered Recipient Entity
WCG IRB
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235940385
Principal investigator 1 Genmab A/S $1,589.00 12/19/2025 Non-covered Recipient Entity
WCG IRB
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235940394
Principal investigator 1 Genmab A/S $2,759.00 12/19/2025 Non-covered Recipient Entity
WCG IRB
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235940398
Principal investigator 1 Kite Pharma, Inc. $75.00 12/16/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066947
Principal investigator 1 Genmab A/S $6,825.00 12/15/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923671
Principal investigator 1 Genmab A/S $6,842.00 12/15/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923714
Principal investigator 1 Genmab A/S $2,809.00 12/15/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923716
Principal investigator 1 Genmab A/S $480.00 12/15/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923723
Principal investigator 1 Genmab A/S $259,350.00 12/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923690
Principal investigator 1 Genmab A/S $365.00 12/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923702
Principal investigator 1 Genmab A/S $1,125.00 12/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923705
Principal investigator 1 Genmab A/S $87,079.00 12/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923729
Principal investigator 1 Genmab A/S $338.00 12/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923740
Principal investigator 1 Genmab A/S $2,387.00 12/12/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930481
Principal investigator 1 Genmab A/S $6,252.00 12/12/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930488
Principal investigator 1 Genmab A/S $2,387.00 12/12/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930495
Principal investigator 1 Genmab A/S $2,387.00 12/12/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930499
Principal investigator 1 Genmab A/S $2,387.00 12/12/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930503
Principal investigator 1 Genmab A/S $900.00 12/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923679
Principal investigator 1 Genmab A/S $1,800.00 12/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923694
Principal investigator 1 Genmab A/S $1,000.00 12/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923733
Principal investigator 1 Genmab A/S $213.00 11/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923683
Principal investigator 1 Genmab A/S $2,720.00 11/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923720
Principal investigator 1 Genmab A/S $213.00 11/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923736
Principal investigator 1 Genmab A/S $2,720.00 11/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923743
Principal investigator 1 BeOne Medicines Ltd. $23,931.00 11/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330899
Principal investigator 1 Genmab A/S $107,583.00 11/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923687
Principal investigator 1 Genmab A/S $6,825.00 11/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923698
Principal investigator 1 Genmab A/S $2,704.00 11/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235923711
Principal investigator 1 BeOne Medicines Ltd. $1,920.00 10/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330847
Principal investigator 1 Kite Pharma, Inc. $41,538.00 10/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066943
Principal investigator 1 Genmab A/S $2,720.00 10/24/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930492
Principal investigator 1 Genmab A/S $213.00 10/24/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930507
Principal investigator 1 Genmab A/S $2,720.00 10/24/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930514
Principal investigator 1 Genmab A/S $2,720.00 10/02/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930484
Principal investigator 1 Genmab A/S $480.00 10/02/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930510
Principal investigator 1 BeOne Medicines Ltd. $2,000.00 09/23/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330885
Principal investigator 1 BeOne Medicines Ltd. $5,425.00 09/23/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330889
Principal investigator 1 BeOne Medicines Ltd. $5,961.00 09/23/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330897
Principal investigator 1 Genmab A/S $480.00 09/08/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930478
Principal investigator 1 BeOne Medicines Ltd. $3,287.00 09/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330843
Principal investigator 1 BeOne Medicines Ltd. $600.00 09/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330891
Principal investigator 1 BeOne Medicines Ltd. $1,200.00 09/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330893
Principal investigator 1 Genmab A/S $1,300.00 08/26/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930450
Principal investigator 1 Kite Pharma, Inc. $3,989.00 08/26/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212066937
Principal investigator 1 Genmab A/S $778.00 08/20/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930447
Principal investigator 1 Genmab A/S $213.00 08/20/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930470
Principal investigator 1 Kite Pharma, Inc. $2,907.00 08/19/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066932
Principal investigator 1 Acerta Pharma LLC $1,864.00 08/13/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
a randomized,multicenter,open label,3 arm phase 3 study of obinutuzumab in combination with chlorambucil,ACP 196 in combination with obinutuzumaband ACP 196 monotherapy in subjects with previously untreated chronic lymphocytic leukemia No dispute reported 06/30/2026 1185538392
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 08/13/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184127944
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,775.01 08/13/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184127946
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,731.00 08/12/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184127942
Principal investigator 1 Genmab A/S $1,300.00 08/06/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930435
Principal investigator 1 Genmab A/S $500.00 08/06/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930466
Principal investigator 1 BeOne Medicines Ltd. $600.00 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330887
Principal investigator 1 BeOne Medicines Ltd. $1,586.00 08/05/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $600.00 07/25/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184127928
Principal investigator 1 Genmab A/S $2,720.00 07/23/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930458
Principal investigator 1 Genmab A/S $2,720.00 07/23/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930462
Principal investigator 1 Kite Pharma, Inc. $1,386.00 07/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,078.72 07/22/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184127924
Principal investigator 1 Kite Pharma, Inc. $354.00 07/15/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy B - Relapsed/Refractory Richter Transformation No dispute reported 06/30/2026 1212066832
Principal investigator 1 Kite Pharma, Inc. $820.00 07/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy B - Relapsed/Refractory Richter Transformation No dispute reported 06/30/2026 1212066826
Principal investigator 1 Genmab A/S $609.00 07/07/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930439
Principal investigator 1 Genmab A/S $4,954.00 07/07/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930442
Principal investigator 1 Genmab A/S $1,690.00 07/07/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930454
Principal investigator 1 Genmab A/S $20,526.00 07/07/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930474
Principal investigator 1 BeOne Medicines Ltd. $1,200.00 07/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330883
Principal investigator 1 Genmab A/S $213.00 06/26/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930388
Principal investigator 1 Genmab A/S $2,720.00 06/26/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930398
Principal investigator 1 Genmab A/S $400.00 06/26/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930406
Principal investigator 1 Genmab A/S $153.40 06/26/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930410
Principal investigator 1 Genmab A/S $213.00 06/26/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930418
Principal investigator 1 Genmab A/S $676.00 06/26/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930426
Principal investigator 1 Genmab A/S $2,720.00 06/26/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930430
Principal investigator 1 BeOne Medicines Ltd. $3,230.00 06/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190326044
Principal investigator 1 BeOne Medicines Ltd. $2,200.00 06/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190326922
Principal investigator 1 Kite Pharma, Inc. $2,000.00 06/24/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,800.00 06/19/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184127526
Principal investigator 1 Kite Pharma, Inc. $800.00 06/17/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 06/13/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184127520
Principal investigator 1 BeOne Medicines Ltd. $4,550.00 06/10/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330901
Principal investigator 1 Kite Pharma, Inc. $780.00 06/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Rituximab or Lenalidomide in Subjects with Refractory Large B-Cell Lymphoma (ZUMA-14) No dispute reported 06/30/2026 1212066906
Principal investigator 1 Kite Pharma, Inc. $1,750.00 06/03/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7) No dispute reported 06/30/2026 1212066910
Principal investigator 1 BeOne Medicines Ltd. $3,287.00 05/30/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190330859
Principal investigator 1 BeiGene, Ltd. $6,786.00 05/20/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190321196
Principal investigator 1 BeiGene, Ltd. $600.00 05/20/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321700
Principal investigator 1 Kite Pharma, Inc. $2,531.00 05/20/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212066892
Principal investigator 1 Kite Pharma, Inc. $9,521.55 05/20/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7) No dispute reported 06/30/2026 1212066898
Principal investigator 1 BeiGene, Ltd. $2,400.00 05/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190322436
Principal investigator 1 Genmab A/S $960.00 05/02/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930391
Principal investigator 1 Genmab A/S $960.00 05/02/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930414
Principal investigator 1 Kite Pharma, Inc. $600.00 05/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212066886
Principal investigator 1 BeiGene, Ltd. $3,541.00 04/29/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321708
Principal investigator 1 Genmab A/S $2,720.00 04/23/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930402
Principal investigator 1 Kite Pharma, Inc. $7,398.00 04/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066880
Principal investigator 1 BeiGene, Ltd. $4,110.00 04/17/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190321194
Principal investigator 1 BeiGene, Ltd. $31,440.00 04/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190323830
Principal investigator 1 Eli Lilly and Company $426.40 04/08/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187873721
Principal investigator 1 Kite Pharma, Inc. $750.00 04/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066873
Principal investigator 1 BeiGene, Ltd. $31,440.00 04/07/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190322190
Principal investigator 1 Genmab A/S $213.00 04/02/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930394
Principal investigator 1 Genmab A/S $2,720.00 04/02/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930422
Principal investigator 1 BeiGene, Ltd. $645.00 04/01/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321706
Principal investigator 1 BeiGene, Ltd. $2,600.00 03/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321702
Principal investigator 1 BeiGene, Ltd. $1,585.00 03/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321704
Principal investigator 1 BeiGene, Ltd. $560.25 03/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190324702
Principal investigator 1 Kite Pharma, Inc. $3,239.00 03/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066866
Principal investigator 1 Genmab A/S $543.00 03/14/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930316
Principal investigator 1 Genmab A/S $543.00 03/14/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930332
Principal investigator 1 Genmab A/S $543.00 03/14/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930340
Principal investigator 1 Genmab A/S $543.00 03/14/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930344
Principal investigator 1 Genmab A/S $543.00 03/14/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930349
Principal investigator 1 Genmab A/S $543.00 03/14/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930361
Principal investigator 1 Genmab A/S $543.00 03/14/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930369
Principal investigator 1 BeiGene, Ltd. $62,880.00 03/12/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190321770
Principal investigator 1 BeiGene, Ltd. $7,724.00 03/11/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190321192
Principal investigator 1 Genmab A/S $2,720.00 03/03/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930354
Principal investigator 1 AstraZeneca Pharmaceuticals LP $101,067.77 02/26/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Modular Phase I and II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium) No dispute reported 06/30/2026 1185538396
Principal investigator 1 BeiGene, Ltd. $3,287.00 02/25/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321548
Principal investigator 1 Kite Pharma, Inc. $3,450.00 02/19/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy B - Relapsed/Refractory Richter Transformation No dispute reported 06/30/2026 1212066819
Principal investigator 1 Kite Pharma, Inc. $1,386.00 02/19/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066864
Principal investigator 1 BeiGene, Ltd. $4,547.00 02/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190321190
Principal investigator 1 Genmab A/S $381.00 02/14/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930311
Principal investigator 1 Acerta Pharma LLC $52,589.29 02/13/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185538394
Principal investigator 1 Genmab A/S $213.00 02/03/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930328
Principal investigator 1 Genmab A/S $2,720.00 02/03/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930346
Principal investigator 1 Genmab A/S $2,720.00 02/03/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930365
Principal investigator 1 Genmab A/S $213.00 02/03/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930380
Principal investigator 1 BeiGene, Ltd. $10,962.00 01/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190321188
Principal investigator 1 BeiGene, Ltd. $7,559.00 01/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321546
Principal investigator 1 BeiGene, Ltd. $645.00 01/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190324704
Principal investigator 1 Kite Pharma, Inc. $440.00 01/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy B - Relapsed/Refractory Richter Transformation No dispute reported 06/30/2026 1212066804
Principal investigator 1 Kite Pharma, Inc. $2,075.00 01/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy B - Relapsed/Refractory Richter Transformation No dispute reported 06/30/2026 1212066808
Principal investigator 1 Kite Pharma, Inc. $13,466.00 01/28/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) - Substudy B - Relapsed/Refractory Richter Transformation No dispute reported 06/30/2026 1212066812
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,164.99 01/27/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1236001118
Principal investigator 1 Janssen Research & Development, LLC $2,550.00 01/23/2025 Covered Recipient Teaching Hospital
Jersey Shore University Med Ctr
A Randomized Open label Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the Firstline Treatment of Subjects with Chronic Lymphocytic Leukemia CLL Small Lymphocytic Lymphoma SLL No dispute reported 06/30/2026 1175337830
Principal investigator 1 Eli Lilly and Company $205,205.54 01/22/2025 Covered Recipient Teaching Hospital
HACKENSACK UNIVERSITY MEDICAL CENTER
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187873719
Principal investigator 1 Genmab A/S $480.00 01/22/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930307
Principal investigator 1 Kite Pharma, Inc. $1,521.00 01/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066858
Principal investigator 1 BeiGene, Ltd. $9,877.00 01/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1190321544
Principal investigator 1 BeiGene, Ltd. $1,200.00 01/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190322682
Principal investigator 1 BeiGene, Ltd. $2,400.00 01/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190322684
Principal investigator 1 Kite Pharma, Inc. $1,275.00 01/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066848
Principal investigator 1 Kite Pharma, Inc. $600.00 01/21/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) No dispute reported 06/30/2026 1212066853
Principal investigator 1 Kite Pharma, Inc. $6,120.00 01/14/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING No dispute reported 06/30/2026 1212066843
Principal investigator 1 Celgene Corporation $221,244.02 01/13/2025 Covered Recipient Teaching Hospital
Jfk University Medical Center
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1222304477
Principal investigator 1 Genmab A/S $960.00 01/10/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930372
Principal investigator 1 Genmab A/S $400.00 01/10/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. No dispute reported 06/30/2026 1235930376
Principal investigator 1 BeiGene, Ltd. $90,720.00 01/08/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190321810
Principal investigator 1 BeiGene, Ltd. $1,000.00 01/06/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190322680
Principal investigator 1 BeiGene, Ltd. $500.00 01/06/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies No dispute reported 06/30/2026 1190322686
Principal investigator 1 Genmab A/S $213.00 01/06/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930320
Principal investigator 1 Genmab A/S $2,720.00 01/06/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930324
Principal investigator 1 Genmab A/S $282.00 01/06/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930336
Principal investigator 1 Genmab A/S $2,720.00 01/06/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930358
Principal investigator 1 Genmab A/S $477.20 01/06/2025 Non-covered Recipient Entity
HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma. No dispute reported 06/30/2026 1235930384